South Africa Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the South Africa Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

South Africa Pharmaceuticals & Healthcare Report
Product Price
$1,345.00

The South Africa Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's South Africa Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Africa pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for South Africa, to test other views - a key input for successful budgeting and strategic business planning in the South African pharmaceutical and healthcare market.
  • Target business opportunities and risks in the South African pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (South Africa 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (South Africa 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2012-2020)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2012-2020)
18
Prescription Drug Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (South Africa 2012-2020)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (South Africa 2012-2020)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (South Africa 2012-2020)
25
OTC Medicine Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (South Africa 2012-2020)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (South Africa 2014-2020)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (South Africa 2014-2020)
30
Industry Risk/Reward Index
31
Middle East And Africa Risk/Reward Index - Q4 2016
31
South Africa Risk/Reward Index
39
Rewards
39
Risks
40
Regulatory Review
41
Table: Drug Classification System
41
Intellectual Property Issues
46
Pricing Regime
49
Table: Tiered Pharmaceutical Pricing System Is Better Than A Flat Fixed Mark-Up
49
Reimbursement Regime
51
Market Overview
52
Healthcare Sector
53
Table: Healthcare Resources (South Africa 2010-2015)
59
Table: Healthcare Personnel (South Africa 2010-2015)
59
Table: Healthcare Activity (South Africa 2010-2015)
60
Research & Development
60
South Africa Pharmaceuticals & Healthcare Report Q4 2016$$
South Africa Pharmaceuticals & Healthcare Report Q4 2016$$
Clinical Trials
61
Epidemiology
65
Competitive Landscape
69
Research-Based Industry
69
Table: Multinational Market Activity
71
Generic Drugmakers
72
Pharmaceutical Retail Sector
73
Company Profile
77
Aspen Pharmacare
77
Adcock Ingram
81
Cipla Medpro
85
GlaxoSmithKline
89
Novartis
93
Pfizer
95
Roche
98
Sanofi
100
Demographic Forecast
103
Demographic Outlook
103
Table: Population Headline Indicators (South Africa 1990-2025)
104
Table: Key Population Ratios (South Africa 1990-2025)
104
Table: Urban/Rural Population & Life Expectancy (South Africa 1990-2025)
105
Table: Population By Age Group (South Africa 1990-2025)
105
Table: Population By Age Group % (South Africa 1990-2025)
106
Glossary
108
Methodology
110
Pharmaceutical Expenditure Forecast Model
110
Healthcare Expenditure Forecast Model
110
Notes On Methodology
111
Risk/Reward Index Methodology
112
Index Overview
113
Table: Pharmaceutical Risk/Reward Index Indicators
113
Indicator Weightings
114